We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

23 hedge funds and large institutions have $3.29M invested in CASI Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.93% less ownership

Funds ownership: 14.61% → 13.67% (-0.93%)

4% less funds holding

Funds holding: 24 → 23 (-1)

36% less capital invested

Capital invested by funds: $5.17M → $3.29M (-$1.88M)

Holders
23
Holders Change
-1
Holders Change %
-4.17%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
8
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$47.1K
2
TRCT
Tower Research Capital (TRC)
New York
+$2.36K
3
Renaissance Technologies
Renaissance Technologies
New York
+$992
4
Vanguard Group
Vanguard Group
Pennsylvania
+$347
5
WPA
West Paces Advisors
Georgia
+$198

Top Sellers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
-$227K
2
Prudential Financial
Prudential Financial
New Jersey
-$29K
3
WSCM
Wellington Shields Capital Management
New York
-$24K
4
Morgan Stanley
Morgan Stanley
New York
-$4.03K
5
UBS Group
UBS Group
Switzerland
-$3.31K

CASI Hedge Fund Activity: Q4 2022 in Review

23 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2022, worth a combined $3.29M — down 36% from $5.17M a quarter earlier.

Fund positioning in CASI was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 8 added to existing stakes and 5 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $47.1K. The largest seller was Federated Hermes, cutting an estimated $227K.

  • 23 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2022, down from 24 in Q3 2022.
  • Funds reported $3.29M of CASI Pharmaceuticals stock for Q4 2022, down 36% quarter-over-quarter.
  • 2 funds opened new CASI Pharmaceuticals positions in Q4 2022 and 2 closed out, a net change of 0 holders.
  • The largest CASI Pharmaceuticals buyer in Q4 2022 was Susquehanna International Group, an estimated $47.1K added.
  • The largest CASI Pharmaceuticals seller in Q4 2022 was Federated Hermes, an estimated $227K sold.

Based on aggregated 13F filings for Q4 2022.